Previous Close | 3.0000 |
Open | 3.0000 |
Bid | 3.0700 x 900 |
Ask | 3.0800 x 800 |
Day's Range | 2.9976 - 3.1900 |
52 Week Range | 2.6600 - 7.3900 |
Volume | 424,822 |
Avg. Volume | 597,971 |
Market Cap | 102.027M |
Beta (3Y Monthly) | 1.77 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.8360 |
Earnings Date | Nov 12, 2019 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | 2014-10-31 |
1y Target Est | 17.17 |
Biotech investment is fraught with risk. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts. These binary events , however, provide an opportunity for making ...
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on November 29, 2019, the Company granted stock options and restricted stock units to one new employee of the Company.
While trade relations and tax-loss selling are causes for concern, opportunities for short-term and swing traders remain abundant.
Q3 2019 Paratek Pharmaceuticals Inc Earnings Call
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) shareholders should be happy to see the share price up 26% in the last...
Paratek (PRTK) delivered earnings and revenue surprises of 5.66% and 8.43%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
-- Third Quarter 2019 NUZYRA® (omadacycline) Net Sales increased 82% versus the Prior Quarter to $3.1 Million -- -- Oral-only CABP Pharmacokinetics Study Initiated-- BOSTON,.
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcast on Tuesday, November 12, 2019 at 4:30 p.m. EDT to report its financial results for the quarter ended September 30, 2019 and provide a corporate update. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call should dial: 855-327-6838 and international investors should dial: 604-235-2082.
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on October 31, 2019, the Company granted stock options and restricted stock units to three new employees of the Company.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Oct. 31) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ...
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced the outcome of its two exploratory Phase 2 clinical studies evaluating the efficacy and safety of its once-daily oral and intravenous (IV) modernized tetracycline omadacycline in patients with two common forms of urinary tract infections (UTI). Both studies were adaptive studies which included multiple dosage regimens of omadacycline with the objective to identify a dose regimen for further investigation that would be clinically and microbiologically effective in each of the UTI indications to be studied. The first Phase 2 study, conducted in the U.S., was designed to evaluate the efficacy, safety, tolerability and pharmacokinetics of oral-only omadacycline compared to an oral-only regimen of nitrofurantoin in female patients with cystitis, or uncomplicated urinary tract infections (uUTI).
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 17) Applied Therapeutics Inc (NASDAQ: APLT ) Arrowhead ...
Application approvable by European Medicine Agency (EMA) for skin infections based on two Phase 3 studiesEMA requesting second study in CABP to meet regulatory standards of two.
52 Presentations by Coalition Members During the Annual Meeting WASHINGTON , Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...
BOSTON, Sept. 25, 2019 -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of.
Paratek Pharmaceuticals (PRTK) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Baupost leader ups bet on biotech company that focuses on genetic diseases Continue reading...
Guru adds to position in biotech company that focuses on genetic diseases Continue reading...
If you own shares in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) then it's worth thinking about how it contributes to...
Paratek Pharmaceuticals, Inc. (PRTK) mourns the loss of Stuart Levy, M.D., who passed way last week. Dr. Levy co-founded the company more than two decades ago along with Dr. Walter Gilbert and was instrumental in the development of Paratek’s lead antibiotic, NUZYRA® and SEYSARA®. “Stuart was a distinguished physician who was the forefront of antibiotic development and a dedicated champion for the prudent use of antibiotics,” said Evan Loh, M.D., Paratek CEO.
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that the Company will present at 21st Annual H.C. Wainwright Global Investment Conference on Monday, September 9 at 11:15 a.m. ET at the Lotte New York Palace Hotel in New York. To access the live webcast of Paratek's presentation, please visit http://wsw.com/webcast/hcw5/prtk/. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics.